Therefore, while acknowledging the limitations of MPFC sensitivity, our findings suggest that MAGE-C1/CT7 could serve as a valuable and more accessible biomarker for prognostication and treatment response monitoring in MM. This evidence concerns the gene MAGEC1 and Miyoshi myopathy.